ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Being the deregulated BCR/ABL kinase activity the cause of CML, targeting its catalytic domain was the most rationale approach for the rational development of small molecules that inhibit ABL kinase activity.